Physician profile
Samir Iskander
NPI 1679531388
$1,376.70
in general payments reported to CMS, 2019-2025
20 companies · $16.72 in 2025
The $16.72 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $105 · 2021: $380 · 2022: $391 · 2023: $239 · 2024: $84.37 · 2025: $16.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $339.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $370.83 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $190.63 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.26 | 2019-2022 | |
| Abbvie INC. | $100.00 | 2023 | |
| Merck Sharp & Dohme LLC | $87.52 | 2019-2021 | |
| Pfizer INC. | $76.17 | 2019-2020 | |
| Lilly USA, LLC | $60.64 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $59.78 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.73 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $44.70 | 2021 | |
| Glaxosmithkline, LLC. | $44.36 | 2022 | |
| Corcept Therapeutics | $29.80 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $26.02 | 2022 | |
| Dexcom, INC. | $23.99 | 2021 | |
| Sunovion Pharmaceuticals INC. | $22.45 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $20.93 | 2023 | Seglentis |
| Xeris Pharmaceuticals, INC. | $18.18 | 2021 | |
| Lifescan, INC. | $14.00 | 2020 | |
| Amarin Pharma, INC. | $13.77 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Iskander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.